Drug intelligence / Profile preview

glutamine

Development stage
Approved
Lead developer
Emmaus Life Sciences
Modality
Small Molecules
Administration
Oral, Intravenous, Parenteral
01

Overview

Glutamine (L-glutamine) is a naturally occurring non-essential amino acid that becomes conditionally essential during periods of metabolic stress, such as major surgery, trauma, or chronic illness. It is the most abundant free amino acid in the human body, primarily synthesized and stored in skeletal muscle. Glutamine serves as a critical fuel source for rapidly proliferating cells, including leukocytes and intestinal enterocytes, thereby supporting immune function and gastrointestinal mucosal integrity. In clinical practice, pharmaceutical-grade glutamine is FDA-approved for the treatment of sickle cell disease (to reduce acute complications) and short bowel syndrome (in combination with growth hormone). It is also widely investigated for its ability to stimulate GLP-1 secretion in metabolic disorders, reduce protein degradation in muscular dystrophies, and mitigate wasting in HIV/AIDS and cancer cachexia.

Brand names
EndariNutreStoreGlutamine Plus
Other names
L-glutamineGLNLevoglutamide2-aminopentanedioic acid 5-amide
02

Targets

GLS1 (Glutaminase 1)GLUL (Glutamine synthetase)SLC1A5 (Alanine/serine/cysteine transporter 2)GLP1R (GLP-1R)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on glutamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glutamine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call